Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease

George L. Barnes,1 Kerri E. Hebert,1 Mohammad Kamal,1 Amjad Javed,2 Thomas A. Einhorn,1 Jane B. Lian,2 Gary S. Stein,2 and Louis C. Gorstenfeld1

1Department of Orthopaedic Surgery, Boston University Medical Center, Boston, and 2Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts

ABSTRACT

The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serious and incurable clinical condition. However, the molecular mechanisms regulating tumor cell expression of factors involved in the generation of osteolytic disease remain elusive. We demonstrated recently that breast cancer cells express the Runx2 transcription factor, essential for bone formation and a regulator of skeletal homeostasis. Our experimental results demonstrate that perturbation of Runx2 regulatory function in tumor cells abolishes their ability to form osteolytic lesions in vivo. In vitro, we show that breast cancer cells inhibit osteoblast differentiation while concurrently enhancing osteoclast differentiation in marrow stromal cell cultures. Disruption of Runx2 activity abrogates both of these cancer cell-mediated effects on bone cells. These results demonstrate that Runx2 expression in breast cancer cells provides a molecular phenotype that enables the interactions between tumor cells and the bone microenvironment that lead to osteolytic disease.

INTRODUCTION

It is widely recognized that breast cancer cells preferentially invade and grow as secondary tumors in bone. In 1889, Stephen Paget (1) proposed the “seed and soil” theory to explain the preferential metastasis of cancers to distant sites. Paget proposed that metastatic cancers, including breast, prostate, and lung, preferentially localize to bone, because they find bone to be a fertile soil on which to grow. The consequence of the successful seeding and growth of breast cancer cells in the bone environment is bone destruction; however, studies demonstrate that cancer cells do not directly erode bone. Instead, most of the induced bone destruction is mediated by the local osteoclasts (2, 3). Histologically, lytic tumors appear adjacent to active osteoclasts on the bone surface being resorbed, and inhibitors of osteoclastic activity, including bisphosphonates, have been successfully used in women with metastatic bone disease to reduce the lytic loss of bone (4, 5).

There is debate currently over the primary mechanism by which breast carcinoma influence osteoclast formation and activity leading to osteolytic lesions. One side of the debate favors a direct influence of breast cancer cells on osteoclast formation. Breast cancer cells have been demonstrated to express several factors known to directly modulate osteoclast formation and activity, including macrophage colony stimulating factor, interleukin (IL) 6, IL-11, and IL-8 (6–10). Studies have experimentally shown the direct induction of osteoclast formation by these tumor-produced factors in vitro. IL-8, in particular, has been shown recently to directly induce osteoclast formation in peripheral blood monocytes (7). Interestingly, these studies additionally demonstrate that IL-8 also acts on osteoblasts inducing increased expression of the osteoclastogenic cytokine, the receptor activator of nuclear factor kB ligand (RANKL). RANKL has been demonstrated to be one of the major inducers of osteoclast formation in bone. Thus, IL-8 appears to have direct and indirect effects on osteoclast formation. A number of other studies also support an indirect mechanism of tumor-induced osteoclast formation by parathyroid hormone-related peptide. As with IL-8, parathyroid hormone-related peptide is expressed in many breast cancers, and parathyroid hormone-related peptide has been reported to induce increased expression of RANKL in osteoblasts (8, 11–14). These studies also demonstrate that neither model breast cancer cell lines (MDA-MB-231, MCF-7, or T47D) nor primary tumors express the primary inductive factor in osteoclast formation, RANKL (11). Thus, data exists supporting both direct tumor-induced osteoclast formation and the indirect induction of osteoclasts by tumor cells through an osteoblast-mediated effect. Neither model is mutually exclusive of the other, and it is likely that tumor cells induce osteoclast formation through a combination of these two mechanisms.

The term osteomimicry has been coined to describe the expression of bone-related genes in metastatic cancers that preferentially localize to skeletal sites. The expression of osteoblast-related genes by tumor cells is thought to play an important role in facilitating the interactions between cancer cells and the bone environment. Breast, prostate, and lung cancers have been demonstrated to express several molecules usually restricted to skeletal cells, including bone sialoprotein (BSP; Refs. 15–19). Our laboratory and others have demonstrated recently that metastatic breast cancer cells express the transcription factor Runx2 [also referred to as core binding factor al/acute myeloid leukemia (AML)-3], and that this transcription factor regulates the expression of skeletal-restricted genes in cancer cells (17–19). Runx2 is one of the primary transcriptional regulators of new bone formation and skeletal maintenance (20–24). Ablation of this gene in mice results in a complete absence of bone formation that is attributed to the arrest of chondrogenic and osteogenic maturation (23, 24). During osteogenesis, Runx2 is expressed in both dividing osteoprogenitors and mature osteoblasts and plays a regulatory role in cellular proliferation and differentiation (25). Runx2 is involved in the expression of soluble factors that mediate angiogenic events (vascular endothelial growth factor), tissue remodeling (matrix metalloproteinases 9 and 13), and the coupling of osteoblasts to osteoclasts (e.g., osteoprotegerin/RANKL; Refs. 26–31). In mature osteoblasts, Runx2 transcriptionally regulates many of the genes associated with mineralization, including osteocalcin, BSP, and collagen type I (23, 24, 32, 33). Thus, this single transcription factor plays a functional role in multiple stage-specific functions of the osteoblast lineage. By extension, Runx2 may regulate multiple factors in metastatic breast cancer cells involved in tumor-bone cell interactions.

Runx family members primarily act as scaffolds or molecular organizers, interacting with coregulatory factors, promoter elements, and specific subnuclear targets in the nuclear matrix (34).
Functional interactions have been demonstrated between the Runx proteins and coregulators, including Groucho/transducin-like enhancer of split (TLE), retinoblastoma protein (Rb) CAAT/enhancer binding protein, yes-associated protein, and the Smads (34–40). Consensus binding elements for Runx2 have been identified in multiple genes associated with skeletal homeostasis, angiogenesis, and mineralization (23, 24, 32, 33). Additionally, appropriate Runx regulatory function requires proper subnuclear targeting of Runx family members (41, 42). A clear example for this requirement is derived from the Runx1-ETO (AML1-ETO) fusion protein that is associated with acute myelogenous leukemia. This gene rearrangement (t(8;21)) fuses the NH2-terminal portion of AML1 (Runx1) to the ETO (MTG8) repressor protein (43, 44). AML1-ETO lacks the intranuclear targeting signal of the wild-type AML1 and is instead targeted by the ETO component to alternate nuclear matrix-associated sites leading to aberrant gene regulation and the leukemic disease. Several researchers have adopted strategies based on the AML1-ETO gene rearrangement for perturbing normal Runx transcriptional regulation in other systems. Specifically, a number of studies have used COOH-terminal deletions of Runx2 as a dominant-negative tool for disrupting endogenous Runx2 activity in skeletal systems both in vivo and in vitro (40, 45–48). These proteins retain DNA binding but completely lack the COOH-terminal sequences involved in coregulatory factor interactions and subnuclear targeting and, thus, are nonfunctional. In the present study, we use this approach to perturb the regulatory functions of the endogenous Runx2 expressed in metastatic breast carcinoma to determine the role of Runx2 in the generation of osteolytic disease.

MATERIALS AND METHODS

**Generation of Stable Cell Lines.** Stable cell lines were generated expressing the empty vector pcDNA 3.1 (Invitrogen Inc., San Diego, CA), full-length hemagglutinin-tagged mouse Runx2 or Xpress epitope-tagged deletion mutant (Runx2 Δ230) in the MDA-MB-231 or LCC15-MB human breast adenocarcinoma cell lines. The full-length hemagglutinin-tagged murine Runx2 or Xpress epitope-tagged deletion mutant (Runx2 Δ230) are as described previously (40). Cells were transfected using LipofectAMINE (Invitrogen Inc.) according to the manufacturer’s instructions and selected based on neomycin resistance (G418; Life Technologies, Inc./Invitrogen Corp., Grand Island, NY). Minimums of four independent clones were tested for each cell line construct combination.

**Western Blot Analysis.** Stable or untransfected cells were rinsed in PBS, trypsinized, and pelleted. Cell pellets were lysed in 300 μl of lysis buffer [25 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 1% NP40, 25 μg MGI132, and protease inhibitor mixture], and 50 μg of protein were resolved on 10% SDS-PAGE. Blots were sequentially probed with monoclonal antibodies against Runx2 (1:3,000), Xpress epitope (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA), and tubulin (1:25,000; Sigma Aldrich Inc.) with the blot stripped between each successive probing.

**Surgical Protocols.** Animal studies are conducted in accordance with approved Institutional Animal Care and Use Committee protocols and the NIH Guide for the Care and Use of Laboratory Animals. Tibial intramedullary injections were carried out on isoflurane anesthetized 4–6-week-old female severe combined immunodeficiency mice (The Jackson Laboratory, Bar Harbor, ME) using the technique described previously (49).

**Preparation of Marrow Stromal Cells.** Bone marrow stromal cell cultures were generated as described previously (11, 50, 51). Five days after initial plating, 2500 (LCC15-MB) or 5000 (MDA-MB-231) human breast cancer cells were added to the cultures unless noted otherwise in text. Cultures were maintained with feeding every 48 h and till harvested at 21 days in α-modified MEM containing 10% fetal bovine serum, Pen/Strep, 10−8 M dexamethasone, 50 μg/ml ascorbic acid, and 8 mM β-glycerophosphate (all of the media and supplements were obtained from Life Technologies, Inc./Invitrogen Corp.).

**Histology.** Injected tibiae were harvested and processed for paraffin embedding using the procedures described previously (51). Paraffin-embedded 5-μm thick sections were prepared and stained with H&E for a standard analysis of tissue sections. The adjacent sections were stained for tartrateresistant acid phosphatase (TRAP) activity as described previously (51).

**Results**

Characterization of Stable Cell Lines with Disrupted Runx2 Activity. In order to directly demonstrate a role for Runx2 in regulating tumor bone cell interactions, we generated a number of stably transfected breast cancer cell lines (both MDA-MB-231 and LCC15-MB based) that overexpressed the previously characterized COOH-terminal deleted mutant Runx2 construct (Delta 230) or the full-length wild-type Runx2 depicted in Fig. 1A (40). Concurrently stable control lines were generated with the empty expression vector. We have reported previously that the Delta 230 construct is translocated to the nucleus and retains DNA binding affinity but does not support an independent transactivation activity for target genes (40). Studies from other laboratories demonstrate that COOH-terminal deleted Runx2 protein functions by competing for DNA target site binding with the endogenous protein but displays...
FIDELITY OF RUNX2 ACTIVITY IN BREAST CANCER CELLS

Radiographically Detectable Lesions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Injected Animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-231 (Control)</td>
<td>16/20 = 80%</td>
</tr>
<tr>
<td>Delta 230 Expressing</td>
<td>1/20 = 5%</td>
</tr>
</tbody>
</table>

**Fig. 2.** Representative results of intramedullary injection experiments comparing control MDA-MB-231 to Δ230 mutant Runx expressing MDA-MB-231 cells. Radiographs of limbs mock injected (A, Mock), injected with empty vector control MDA-MB-231 cells (B and C, CTL), or injected with mutant Runx2 expressing cells (D, Delta 230) are shown. White arrows designate sites of visible osteolytic lesions. E and G display H&E sections of stained tibial tumors from control or Delta 230-injected limbs (×20 magnification). Adjacent sections stained for tartrate resistant acid phosphatase-positive osteoclasts associated with control MDA-MB-231 (F) or Delta 230 Runx2 cells (H). Osteoclast-positive staining indicated in F by black arrows. TRAP, tartrate resistant acid phosphatase.

A higher DNA binding affinity and forms more stable protein DNA complexes than the wild-type molecules and, thus, acts as a potent competitive inhibitor (45). Functionally, these studies, as well as other in vivo studies, demonstrate that these mutant Runx2 proteins compete for and inhibit endogenous Runx2 gene regulatory functions (40, 45–48).

For these studies, individual clonal cell lines were isolated after transfection of parental MDA-MB-231 or LCC15-MB breast adenocarcinoma cell lines with the mutant expression constructs and analyzed for transgene expression by Western blotting (representative blot displayed in Fig. 1B). On the basis of our previous studies demonstrating that Runx2 acts as a positive regulator of BSP expression in human breast cancer cells, each cell line was additionally assessed for relative BSP promoter activity as a read-out for transgene inhibitory activity. Only cell lines that displayed a significant reduction in BSP promoter activity (>50% reduction) were selected for use in the subsequent studies (data not shown).

**Disruption of Runx2 Activity in Breast Cancer Cells Abolishes the Formation of Osteolytic Lesions in Vivo.** We initially compared the osteolytic activity of the MDA-MB-231 human breast cancer cell line engineered to stably overexpress the COOH-terminal deleted Runx2, Delta 230, to the empty expression vector-transfected control line in an in vivo implantation model in immunocompromised severe combined immunodeficiency mice. In this model, cancer cells are injected directly into the intramedullary space of the tibia of a hind limb at a location where lytic lesions are commonly observed clinically in human cancers. Radiographic imaging of injected bones 8 weeks after implantation demonstrates that 80% (16 of 20) of control MDA-MB-231 cell-injected limbs display large, detectable osteolytic lesions (Fig. 2). In contrast, of the mice injected with the mutant Runx2 (Delta 230) expressing MDA-MB-231 cells, only 5% (1 of 20) displayed radiographically detectable lesions. Histologically, the control line-associated lesions were large and surrounded by active osteoclasts as indicated by the extensive numbers of TRAP-positive staining cells along the tumor bone interface (Fig. 2F). The single lesion detected in mutant Runx2-injected limbs (1 of 20) was significantly smaller than controls and was not associated with TRAP-positive osteoclasts (Fig. 2H). These results demonstrate that the perturbation of Runx2 regulatory function in breast cancer cells abolishes the ability of these cells to generate osteolytic lesions in bone.

**Breast Cancer Cells Inhibit Osteoblast Differentiation in Vitro While Enhancing Osteoclast Differentiation.** We next pursued a series of in vitro studies to define the response of bone marrow-derived stromal cells to metastatic breast carcinoma cells. We compared two independent human breast cancer cell lines, MDA-MB-231 and LCC15-MB, representing human breast adenocarcinoma of variable aggressiveness. The LCC15-MB, originally isolated from bone metastases in a breast cancer patient, is the more aggressive and displayed a higher relative level of Runx2 protein (Fig. 1B). Five thousand cells/well of each breast cancer cell line was cocultured with 15 × 10⁴ BMSC derived from C57BL/6J mice (11). Both human breast cancer cell lines inhibited osteoblastic differentiation of the BMSC as determined by counting the number of mineralized osteogenic colonies that formed (Fig. 3A). Individual nodules in these cultures represent an osteoblast colony that arises from the differentiation of an individual stem cell population (colony-forming unit), and, therefore, the nodule area represents the proliferation of that stem cell population (49). Coculture with tumor cells also reduced individual nodule areas by 5–10-fold (Table 1). Osteogenic differentiation was additionally assessed biochemically by alkaline phosphatase activity and through the use of RPA of mature osteoblast-associated gene expression (BSP, osteocalcin, and collagen type I; Fig. 3, B and C, respectively). Coculture with the LCC15-MB cells nearly completely inhibited osteogenic differentiation of BMSC (nODULES and alkaline phosphatase activity) and expression of bone phenotypic genes. All of the three parameters demonstrate an inhibition of mature osteoblast formation in cultures containing the breast cancer cells.

To demonstrate that our results were specific for the response of the murine marrow stromal cell population, we hybridized our human cellular RNAs to the murine species-specific RPA probes (Fig. 3D). In each template set used in these studies, the human RNAs did not hybridize to the specific murine-target gene probes; however, the human RNAs did hybridize with the internal control L32 probe producing an alternate-sized protected product. This result allows for an independent evaluation of human versus mouse cellular levels in coculture and shows that control and mutant Runx2 expressing human breast cancer cells do not grow at significantly different rates (compare H.L32 to M.L32 bands in Fig. 5B, Laner 2 and 3) in correlation with independent in vitro proliferation assays on these cell lines (data not shown).

We next examined the effect of coculture on the appearance of BMSC-derived osteoclasts. Our results demonstrate that in contrast to the inhibition of osteoblast differentiation, human breast cancer cells induce an increase in osteoclast cell differentiation in BMSC. Our results show an overall increase in TRAP-positive staining cells and an increased number of multinucleated TRAP-positive staining cells (Fig. 4, A–F). Thus, the breast cancer cells increase TRAP + cell numbers (~2-fold in cultures containing MDA-MB-231 and 3-fold
with LCC15-MB) but also osteoclast maturity as displayed by the increased number of multinucleated TRAP + staining cells. Molecular analyses using RPA demonstrated increased levels of TRAP gene expression, a marker of osteoclasts (Fig. 4G). Thus, breast cancer cells inhibit osteogenic differentiation while concurrently enhancing osteoclast differentiation. The inhibition of osteoblast differentiation combined with increased osteoclast differentiation is consistent with the conditions that would maximally produce a localized osteolytic bone loss.

Runx2 Regulates Breast Cancer Cell-Mediated Inhibition of Osteogenic Differentiation in Vitro. Additional coculture experiments demonstrate that Runx2 regulatory function within the breast cancer cells is required for the tumor cell-associated inhibition of osteogenesis. Although control cancer cells inhibit osteoblast maturation, cocultures of BMSC with MDA-MB-231 (5000 cells/well) or LCC15-MB (2500 cells/well) that overexpress the Runx2, Delta 230 construct show comparable levels of mature osteoblasts to the control BMSC (Fig. 5A). Disruption of the endogenous Runx activity in these breast cancer cells rescued both the number of mineralized nodules formed and individual node area showing that tumor cells inhibit both osteogenic stem cell differentiation and proliferation (Fig. 5A; Table 1). Using RNase protection assays, we demonstrate that disruption of Runx2 activity in these cancer cell lines also rescues BMSC-associated expression of mature osteoblast marker genes, specifically bone BSP and osteocalcin, widely used markers of mature osteoblasts, in correlation with nodule formation (Fig. 5B, left). Thus, perturbation of Runx2 transcriptional functions in breast cancer cells rescued osteoblast differentiation in cocultures.

In contrast, overexpression of Runx2 in MDA-MB-231 cells produces an increased inhibition in osteoblast differentiation as determined by Von Kossa staining of osteoblast-associated mineralized nodule formation (data not shown) and the decreased expression of osteoblast-associated genes (Fig. 5B, right).

**Runx2 Regulates Breast Cancer Cell Induction of Osteoclast Formation and Marrow Stromal Cell Expression Cytokines That Regulate Osteoclastogenesis.** Disruption of the endogenous Runx2 activity in human breast cancer cells also reduces osteoclast formation in cancer BMSC cocultures. Although cocultures containing control cancer cells displayed an increased expression of TRAP, overexpression of the mutant Runx construct in either the MDA-MB-231 or LCC15-MB cell line abrogated this osteoclast differentiation effect (Fig. 6, A and B). An analysis of murine stromal cell expression of preresorptive cytokines in cocultures demonstrates that tumor cells elicited an increase in the BMSC-associated expression of multiple cytokines known to influence osteoclast differentiation (Fig. 7). Specifically, our results show that breast cancer cells enhanced BMSC expression of inducible nitrous oxide, tumor necrosis factor α, RANKL, and IL-6, each of which is known to enhance osteoclast differentiation, activity, and/or survival (8, 11–14). RANKL, specifically, is one of the primary inductive factors of new osteoclast differentiation and has been associated with the generation of osteolysis (13). Disruption of Runx2 activity with the mutant Runx construct abolished the increased expression of these osteoclastogenic cytokines demonstrating that Runx2 is a regulator of the influence of the cancer cell on multiple factors within the bone marrow microenvironment that affect osteoclast differentiation (Fig. 7).

**DISCUSSION**

The osteolytic disease associated with metastases of carcinoma in bone is the consequence of two related events. The first is the
ability of the tumor cells to seed and grow in the ectopic environment. This requires that the tumor cells be capable of responding to the local morphogens in the new environment. The second component is the ability of tumor cells to produce factors that modify the local environment, thus, additionally enhancing the growth of these tumors. This is commonly referred to as the "viscous cycle" and represents the efforts of the cancer to mobilize increasing amounts of morphogens by increasing bone removal and the release of the factors sequestered in the bone matrix (2, 8, 11–14). Thus, the osteolytic bone destruction associated with metastases is not an aberrant influence of cancer cells on bone, but rather the purposeful mobilization of morphogens sequestered in bone for the benefit of tumor cells.

In the studies presented here, we have used both in vivo and in vitro models to functionally test the importance of Runx2 in regulating the interactions between breast cancer cells and the bone microenvironment. In vivo, we have used a model of direct injection of human breast cancer cells in the marrow cavity (intramedullary space) of the tibial bone. This model allows for the growth and disease associated with the cancer cells to occur in the specific environment they find after metastasis. Our results demonstrate that perturbation of Runx2 regulatory function in breast cancer cells abolishes their ability to form osteolytic lesions in bone (Fig. 2). We observe that cells expressing mutant Runx2 do not form tumors when injected, independ-

Fig. 4. Human breast cancer cells mediate disruptions of normal murine bone marrow stromal cell osteoclast differentiation in an in vitro coculture. A–F, representative photomicrographs of histochemical staining for osteoclast lineage-associated cellular tartrate resistant acid phosphatase (TRAP) activity in bone marrow stromal cell control versus MDA-MB-231 cancer cell cocultures. A and B, low magnification pictures of individual well of six-well plate. C and D, ×20 magnification of individual cellular staining in a representative field. Note control cultures contain predominantly TRAP-positive cells with single nuclei as compared with cocultures that contain multinucleated (3+) as indicated by arrows. E, ×40 magnification of single nucleated TRAP-positive cell in control bone marrow stromal cell cultures (arrow). F, ×40 magnification of multinucleated (3+) TRAP-positive cells in coculture with MDA-MB-231 cancer cells (arrows). G, graphical representation of normalized TRAP expression. bars, ±5D.

Fig. 5. Cancer cell-mediated disruptions of osteoblast differentiation require Runx2 activity in breast cancer cells. A, representative picture of Von Kossa staining of osteoblast-associated mineralized nodule formation in marrow stromal cell cocultures alone (MSC alone) or with cancer cells expressing either empty vector (control) or the mutant Runx2 construct as indicated in the panel. B, RNase protection analysis of osteoblast-associated gene expression in marrow stromal cells cultured alone (B, Lane 1), coculture with control cancer cells, MDA-MB-231 or LCC15-MB as designated in the figure (Lane 2), coculture with Delta 230 Runx2 expressing MDA-MB-231 or LCC15-MB cancer cells (Lane 3), or MDA-MB-231 cancer cells overexpressing Runx2 (Lane 4, right). Osteoblast-associated genes include osteopontin (OPN), bone sialoprotein (BSP), collagen type I (Col I), and osteocalcin (OC). Murine L32 (M.L32) and human L32 (H.L32) bands are indicated on the figure.
ent of the appearance of osteolytic lesions, suggesting that disruption of Runx2 impacts the breast cancer cell growth in bone. We also observed that the lesion formed in limbs injected with breast cancer cells expressing mutant is not associated with active osteoclasts. This observation shows that independent of growth, tumor cells lacking intact Runx2 function do not activate local osteoclasts. This is consistent with our in vitro data (Fig. 6). Thus, our results support the conclusion that Runx2 activity is required for both the response of tumor cells to the bone environment and the influence of tumor cells on bone cell differentiation.

The second model used in these studies is an in vitro coculture system of breast cancer cells mixed with bone marrow-derived stromal cells representing the cellular compartment of the bone. These cocultures allow for the independent analysis of the responses of both the bone marrow stromal elements and the human cancer cells through the use of species-specific genetic probes. In our current studies, we focus on the response of local bone cells through the use of species-specific probes and analysis of specific genes associated with the osteoblast and osteoclast differentiation. Our experimental results demonstrate that human breast cancer cells inhibit osteoblast maturation in these cocultures while con-

currently enhancing osteoclast formation. In addition, we demonstrate that tumor cells elicit an increase in the BMSC expression of cytokine inducers of osteoclast formation and activity. It has been reported previously that cancer cells induce enhanced expression of RANKL in osteoblasts in response to either IL-8 or parathyroid hormone-releasing protein and that this may be the result of a switch from the bone forming to the osteoclast coupling functions in osteoblasts (7, 8, 11–14). Our data support this conclusion and additionally suggest that the coupling function of osteoblasts is primarily carried out by immature osteoblasts given the observed inhibition of osteoblast maturation concomitant with the increased expression of inductive cytokines. This conclusion is supported by

![Image](76x368 to 264x748)

![Image](341x176 to 527x592)
the recent report demonstrating that RANKL is produced primarily by immature osteoblasts (52).

Perturbation of Runx2 function in the human breast cancer cells demonstrates that Runx2 regulates the influence of cancer cells on the local bone cellular compartment. Overexpression of the mutant Runx2 construct in either the MDA-MB-231 or LCC15-MB cells abolished the tumor cell-associated inhibition of osteoblast maturation (Fig. 5; Table 1), enhanced osteoclast formation, and the increased BMSC expression of cytokines that induce osteoclast formation and activity (Figs. 6 and 7, respectively). Although our results do not discriminate between direct and indirect influences of tumor cells on osteoclast differentiation, these results are consistent with the model proposed previously in which the primary influence of metastatic breast carcinoma cells is on the osteoblast (8, 11–14). Our data specifically demonstrate that the primary influence of breast cancer cells on osteoblasts is an inhibition of their maturation. The inhibition of osteoblast differentiation and associated new bone formation alone would lead eventually to localized bone loss. Such an inhibition would also generate an increase in the local number of immature osteoblasts and, thus, explain the observed associated increase in the expression of the cytokines that induce osteoclast formation expressed by these cells. An increase in the number of osteoclasts would be favored under these conditions leading to an increased rate of bone removal and osteolytic destruction of local bone. Thus, our results suggest breast cancer cells generate osteolytic disease by concurrently inhibiting new bone formation and enhancing localized bone removal. Our experimental results demonstrate that fidelity of Runx2 function in human metastatic breast cancer cells is required for tumor cells to elicit both of these effects on bone.

ACKNOWLEDGMENTS

We thank Cory Edgar and Jennifer Fitch for technical assistance during the course of these experiments and Dr. Andre Van Wijnen for critical reading of the manuscript.

REFERENCES

Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease

George L. Barnes, Kerri E. Hebert, Mohammad Kamal, et al.

Cancer Res 2004;64:4506-4513.

Updated version Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/13/4506

Cited articles This article cites 49 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/13/4506.full.html#ref-list-1

Citing articles This article has been cited by 17 HighWire-hosted articles. Access the articles at:
/content/64/13/4506.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.